Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, T-cell and B-cell Immunology, and Immune Cell Function and Interaction.
Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2
Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche
IL-33 drives polyfunctionality and antitumor activity of a unique ST2+ NK cell population
ZEB1 transcription factor promotes immune escape in melanoma
Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80<sup>+</sup> PDL1<sup>−</sup>)‐pDC subset negatively correlated with clinical outcomes in melanoma patients
Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4 <sup>+</sup> and CD8 <sup>+</sup> T‐cell protective responses to breast cancer
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival
Durable and controlled depletion of neutrophils in mice
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
CD163<sup>+</sup> tumor‐associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes
BDCA1<sup>+</sup> cDC2s, BDCA2<sup>+</sup> pDCs and BDCA3<sup>+</sup> cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
Neutrophil Heterogeneity in Cancer: From Biology to Therapies
Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection
Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration
Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells
Cross Talk between Inhibitory Immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells
A Milestone Review on How Macrophages Affect Tumor Growth
A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage
Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Breast cancer‐derived transforming growth factor‐β and tumor necrosis factor‐α compromise interferon‐α production by tumor‐associated plasmacytoid dendritic cells
ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4<sup>+</sup>T cells by plasmacytoid dendritic cells
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression